David W Pook
Overview
Explore the profile of David W Pook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conduit C, Inderjeeth A, Allen R, Martin A, Parulekar W, Mulroe E, et al.
Future Oncol
. 2025 Jan;
21(6):627-636.
PMID: 39819293
No abstract available.
2.
Pemberton L, Allen C, Handel E, Weickhardt A, Shapiro J, Tran B, et al.
Clin Genitourin Cancer
. 2024 Feb;
22(2):580-585.
PMID: 38402090
Introduction: Many clinicians consider carboplatin monotherapy in advanced castrate-resistant prostate cancer (CRPC) patients who have progressed through all available hormonal and standard chemotherapy treatment options, despite the limited evidence to...
3.
Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K, et al.
Lancet Oncol
. 2023 Mar;
24(4):323-334.
PMID: 36990608
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report...
4.
Stockler M, Martin A, Davis I, Dhillon H, Begbie S, Chi K, et al.
J Clin Oncol
. 2021 Dec;
40(8):837-846.
PMID: 34928708
Purpose: We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality...
5.
Sweeney C, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
Eur Urol
. 2021 May;
80(3):275-279.
PMID: 34030924
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden...
6.
Huddart R, Siefker-Radtke A, Balar A, Bilen M, Powles T, Bamias A, et al.
Future Oncol
. 2020 Sep;
17(2):137-149.
PMID: 32938232
The choice of first-line therapy for patients with metastatic urothelial cancer (mUC) is based on cisplatin-eligibility and programmed death-ligand 1 (PD-L1) status. For patients with mUC who are ineligible for...
7.
Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S, et al.
N Engl J Med
. 2019 Jun;
381(2):121-131.
PMID: 31157964
Background: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or...
8.
Gulley J, Borre M, Vogelzang N, Ng S, Agarwal N, Parker C, et al.
J Clin Oncol
. 2019 Mar;
37(13):1051-1061.
PMID: 30817251
Purpose: PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study...
9.
Lawrence M, Pook D, Wang H, Porter L, Frydenberg M, Kourambas J, et al.
Prostate
. 2015 Jul;
75(13):1475-83.
PMID: 26177841
Background: Fresh patient specimens of castrate-resistant prostate cancer (CRPC) are invaluable for studying tumor heterogeneity and responses to current treatments. They can be used for primary patient-derived xenografts (PDXs) or...
10.
Clark A, Taubenberger A, Taylor R, Niranjan B, Chea Z, Zotenko E, et al.
Biomaterials
. 2013 Apr;
34(20):4777-85.
PMID: 23562048
Stromal-epithelial cell interactions play an important role in cancer and the tumor stroma is regarded as a therapeutic target. In vivo xenografting is commonly used to study cellular interactions not...